An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease

Sony Mathews, Ashley Reid, Chenlu Tian, Qiang Cai

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Gastroesophageal reflux disease (GERD) is a chronic, recurrent disease that affects nearly 19 million people in the US. The mainstay of therapy for GERD is acid suppression. Proton pump inhibitors (PPIs) are the most effective medication for both initial treatment and maintenance therapy of GERD. Pantoprazole, a first-generation PPI, was approved by the FDA in 2000 for the treatment of erosive esophagitis associated with GERD. It has been used in more than 100 different countries worldwide. It is one of the few PPIs available in multiple forms: a delayed-release oral capsule, oral suspension, and intravenous. Pantoprazole been shown to improve acid reflux-related symptoms, heal esophagitis, and improve health-related quality of life more effectively than histamine-2 receptor antagonists. Evaluated in over 100 clinical trials, pantoprazole has an excellent safety profile, is as efficacious as other PPIs, and has a low incidence of drug interactions. It has also been shown to be safe and effective in special patient populations, such as the elderly and those with renal or moderate liver disease.

Original languageEnglish (US)
Pages (from-to)11-16
Number of pages6
JournalClinical and Experimental Gastroenterology
Volume3
Issue number1
StatePublished - Apr 29 2010

Fingerprint

Proton Pump Inhibitors
Gastroesophageal Reflux
Esophagitis
Histamine Receptors
Acids
Therapeutics
Drug Interactions
Capsules
Liver Diseases
Suspensions
Chronic Disease
Quality of Life
Clinical Trials
Kidney
Safety
pantoprazole
Incidence
Population

Keywords

  • Esophagitis
  • GERD
  • Pantoprazole

ASJC Scopus subject areas

  • Gastroenterology

Cite this

An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. / Mathews, Sony; Reid, Ashley; Tian, Chenlu; Cai, Qiang.

In: Clinical and Experimental Gastroenterology, Vol. 3, No. 1, 29.04.2010, p. 11-16.

Research output: Contribution to journalReview article

@article{e5d6b88266b740f1aabbfc042e5eda4e,
title = "An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease",
abstract = "Gastroesophageal reflux disease (GERD) is a chronic, recurrent disease that affects nearly 19 million people in the US. The mainstay of therapy for GERD is acid suppression. Proton pump inhibitors (PPIs) are the most effective medication for both initial treatment and maintenance therapy of GERD. Pantoprazole, a first-generation PPI, was approved by the FDA in 2000 for the treatment of erosive esophagitis associated with GERD. It has been used in more than 100 different countries worldwide. It is one of the few PPIs available in multiple forms: a delayed-release oral capsule, oral suspension, and intravenous. Pantoprazole been shown to improve acid reflux-related symptoms, heal esophagitis, and improve health-related quality of life more effectively than histamine-2 receptor antagonists. Evaluated in over 100 clinical trials, pantoprazole has an excellent safety profile, is as efficacious as other PPIs, and has a low incidence of drug interactions. It has also been shown to be safe and effective in special patient populations, such as the elderly and those with renal or moderate liver disease.",
keywords = "Esophagitis, GERD, Pantoprazole",
author = "Sony Mathews and Ashley Reid and Chenlu Tian and Qiang Cai",
year = "2010",
month = "4",
day = "29",
language = "English (US)",
volume = "3",
pages = "11--16",
journal = "Clinical and Experimental Gastroenterology",
issn = "1178-7023",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease

AU - Mathews, Sony

AU - Reid, Ashley

AU - Tian, Chenlu

AU - Cai, Qiang

PY - 2010/4/29

Y1 - 2010/4/29

N2 - Gastroesophageal reflux disease (GERD) is a chronic, recurrent disease that affects nearly 19 million people in the US. The mainstay of therapy for GERD is acid suppression. Proton pump inhibitors (PPIs) are the most effective medication for both initial treatment and maintenance therapy of GERD. Pantoprazole, a first-generation PPI, was approved by the FDA in 2000 for the treatment of erosive esophagitis associated with GERD. It has been used in more than 100 different countries worldwide. It is one of the few PPIs available in multiple forms: a delayed-release oral capsule, oral suspension, and intravenous. Pantoprazole been shown to improve acid reflux-related symptoms, heal esophagitis, and improve health-related quality of life more effectively than histamine-2 receptor antagonists. Evaluated in over 100 clinical trials, pantoprazole has an excellent safety profile, is as efficacious as other PPIs, and has a low incidence of drug interactions. It has also been shown to be safe and effective in special patient populations, such as the elderly and those with renal or moderate liver disease.

AB - Gastroesophageal reflux disease (GERD) is a chronic, recurrent disease that affects nearly 19 million people in the US. The mainstay of therapy for GERD is acid suppression. Proton pump inhibitors (PPIs) are the most effective medication for both initial treatment and maintenance therapy of GERD. Pantoprazole, a first-generation PPI, was approved by the FDA in 2000 for the treatment of erosive esophagitis associated with GERD. It has been used in more than 100 different countries worldwide. It is one of the few PPIs available in multiple forms: a delayed-release oral capsule, oral suspension, and intravenous. Pantoprazole been shown to improve acid reflux-related symptoms, heal esophagitis, and improve health-related quality of life more effectively than histamine-2 receptor antagonists. Evaluated in over 100 clinical trials, pantoprazole has an excellent safety profile, is as efficacious as other PPIs, and has a low incidence of drug interactions. It has also been shown to be safe and effective in special patient populations, such as the elderly and those with renal or moderate liver disease.

KW - Esophagitis

KW - GERD

KW - Pantoprazole

UR - http://www.scopus.com/inward/record.url?scp=77953418607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953418607&partnerID=8YFLogxK

M3 - Review article

VL - 3

SP - 11

EP - 16

JO - Clinical and Experimental Gastroenterology

JF - Clinical and Experimental Gastroenterology

SN - 1178-7023

IS - 1

ER -